chufangao/CTO huggingface dataset:
Clinical trial NCT04603742: Anakinra, COVID-19, Cytokine Storm
Official title: Anakinra in Adults With Severe COVID-19 and Features of Cytokine Storm Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Acronym: SOBI
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding did not go through
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2022-06-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04128020: Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Official title: Phase I Trial of Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Big Ten Cancer Research Consortium BTCRC-AML18-342
Sponsor: Big Ten Cancer Research Consortium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funder withdrew funding after not accruing any subjects after 1 year.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-10
Primary completion date: 2020-09-28
Completion date: 2020-09-28
Plan to share individual participant data: NO
Clinical trial NCT03489850: Ibudilast and Withdrawal-Related Dysphoria
Official title: Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-16
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT02924727: Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
Official title: A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI)
Acronym: PARADISE-MI
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 5669.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-09
Primary completion date: 2021-02-26
Completion date: 2021-02-26
Baseline population: The Full Analysis Set (FAS) consisted of 5661 patients and consisted of patients in the Randomized population who were not mis-randomized patients. Out of the 5669 patients randomized, a total of 8 patients were mis-randomized, 4 from each treatment group. Following the intent-to-treat (ITT) principle, patients in the FAS were analyzed according to the treatment they were assigned to at randomization.
Limitations and caveats: In this study there were 25 patients who did not take study treatment after randomization, and thus were not included in the safety set.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05472662: A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
Official title: A Single-dose, Randomised, Double-blind, Controlled, 2-way Cross-over Study to Assess the Potential for Bronchoconstriction of the New Propellant HFA-152a Versus the Marketed HFA-134a Propellant, in Adult Subjects With Mild Asthma
Sponsor: Chiesi Farmaceutici S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-03
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Official title: A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
Acronym: Cornerstone001
Sponsor: Aston Sci. Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty in recruiting patients
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-28
Primary completion date: 2024-05-31
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT05223699: Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Official title: A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Sponsor: Magenta Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 22.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-14
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Clinical trial NCT04870801: An Alternative Way To Deliver Oxygen To People
Official title: Evaluation of Respirogen Oxygen Microbubble Technology: Efficacy for Human Use During Rest in Normal and Low-oxygen Environments
Sponsor: Colorado State University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The project was denied funding and the protocol was subsequently closed. No participants were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Plan to share individual participant data: NO
Clinical trial NCT03994731: Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])
Acronym: MIRROR RCT
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-13
Primary completion date: 2021-03-17
Completion date: 2022-04-11
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT05441930: A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Official title: An Interventional, Open Label, Controlled, Randomized, Pairwise, Phase Ib Safety, Tolerability and Pharmacokinetic (PK) Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Sponsor: PolyActiva Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor has suspended study to conserve capital for clinical development of lead asset
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-06-23
Primary completion date: 2023-12-15
Completion date: 2024-03-14
Plan to share individual participant data: NO
Clinical trial NCT03943446: A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period.
Enrollment: 34.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-04
Primary completion date: 2022-08-25
Completion date: 2022-08-25
Baseline population: Full analysis set (FAS) included all participants to whom study treatment had been assigned by randomization and received at least 1 dose of study drug.
Limitations and caveats: This study is terminated as the sponsor decided to discontinue study due to inability to recruit the expected number of participants within the requisite time period.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04420299: Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19
Official title: A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19
Sponsor: Fundación de investigación HM (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding of the non-commercial sponsor to extend recruitment and reach the target number of patients specified in the protocol.
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-04
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Plan to share individual participant data: NO
Clinical trial NCT05083078: A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
Official title: A Phase 1 Study to Assess the Relative PK and Tissue Distribution of Guselkumab and Risankizumab in Healthy Participants and Patients With Psoriatic Arthritis
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was stopped due to unanticipated feasibility constraints.
Enrollment: 11.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-04
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02725268: A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Official title: A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 241.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-04-01
Primary completion date: 2019-07-02
Completion date: 2020-10-30
Baseline population: Intent-to-treat (ITT) population included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Clinical trial NCT03985423: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
Official title: A Phase 2/3, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emapalumab in Adult Patients With Hemophagocytic Lymphohistiocytosis
Sponsor: Swedish Orphan Biovitrum (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-02
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Baseline population: The All Treated analysis set included all patients who received at least 1 dose or 1 incomplete dose of emapalumab.
Limitations and caveats: Since the study was prematurely terminated, and considering the low number of patients enrolled, no analysis related to primary and secondary efficacy endpoints and no Pharmacokinetic and Pharmacodynamic summary statistics were performed. Accordingly, no conclusion on the efficacy of emapalumab on this patient population could be withdrawn from the study.
Plan to share individual participant data: NO
Clinical trial NCT04644484: A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Official title: A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks
Sponsor: Synermore Biologics (Suzhou) Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1000.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-23
Primary completion date: 2022-06-24
Completion date: 2022-12-16
Plan to share individual participant data: NO
Clinical trial NCT05001555: Efficacy and Safety of Dexketoprofen/Vitamin B vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II
Official title: Efficacy and Safety of the Combination Dexketoprofen / Vitamin B vs Dexketoprofen in the Treatment of Pain in Patients With Post-traumatic Cervical Sprain Grade I-II of the Quebec Scale.
Acronym: WHIPLASH
Sponsor: Laboratorios Silanes S.A. de C.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 174.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-23
Primary completion date: 2023-04-24
Completion date: 2023-04-25
Plan to share individual participant data: NO
Clinical trial NCT04401579: Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
Official title: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1033.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-08
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT05020483: FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients
Official title: Activated Prothrombin Complex Concentrate FEIBA to Optimize Postcardiopulomonary Bypass Hemostasis in Pediatric Cardiac Patients
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Patient population changed and no subjects eligible for the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT03712449: A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment
Official title: Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 59.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-22
Primary completion date: 2020-07-29
Completion date: 2020-07-29
Baseline population: Full Analysis Population included all participants who had met all eligibility criteria at the screening visit and received any product used as treatment in this study.
Plan to share individual participant data: NO
Clinical trial NCT03322566: A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Official title: A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 233.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-01-09
Primary completion date: 2018-12-13
Completion date: 2020-10-16
Baseline population: Intent-to-treat (ITT) population included all participants who were randomized to study intervention.
Limitations and caveats: Data from the final analysis of KEYNOTE-715/ECHO-306 (data cutoff: 13-DEC-2018) indicated that the study did not meet the pre-specified endpoint of improvement in objective response rate (ORR).
Plan to share individual participant data: NO
Clinical trial NCT04211363: Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Official title: A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
Acronym: DERMIS-1
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 439.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-20
Primary completion date: 2020-11-16
Completion date: 2020-11-16
Plan to share individual participant data: NO
Clinical trial NCT03738917: Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.
Official title: Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Uncomplicated Acute Bronchitis.
Acronym: AB4T
Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 668.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-02-01
Primary completion date: 2021-11-30
Completion date: 2021-12-31
Plan to share individual participant data: YES
IPD sharing description: Reposition of data in Scientia
IPD time frame: 2021
IPD access criteria: Scientia
Clinical trial NCT05297045: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy
Sponsor: Regor Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to financial constraint.
Enrollment: 17.0 (ACTUAL)
Number of arms: 7.0
Start date: 2022-03-29
Primary completion date: 2023-05-30
Completion date: 2023-05-30
Clinical trial NCT01024920: Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Official title: A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 99.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-12-16
Primary completion date: 2011-11-08
Completion date: 2020-06-19
Baseline population: Treated set: all patients who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.
Clinical trial NCT02985190: A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
Official title: A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Sponsor: Groupe Francophone des Myelodysplasies (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-26
Primary completion date: 2021-09-02
Completion date: 2022-08-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03936270: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Official title: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Sponsor: Latin American Cooperative Oncology Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-05
Primary completion date: 2022-01-18
Completion date: 2023-05-02
Plan to share individual participant data: NO